Trends & Analysis Posts
Trends & Analysis
PAIs and 483 Issuance Risk: The Trends Are Not What They Seem
redica
September 8, 2022
Trends & Analysis
Instant Download | Analysis of 2021 U.S. FDA 483 GMP Observations
Barbara W. Unger
May 3, 2022
Trends & Analysis
Instant Download | Yes, Warehouses Must Comply with Relevant GMPs
Barbara W. Unger
March 8, 2022
Trends & Analysis
Instant Download | FY2020 and FY2021 Drug GMP Warning Letter Analysis
Barbara W. Unger
February 11, 2022
Trends & Analysis
Instant Download | Analysis of COVID-19 Vaccine and Drug 483s
Barbara W. Unger
January 25, 2022
Trends & Analysis
How Small Pharma Firms Can Prepare for a GMP Inspection
Barbara W. Unger
June 30, 2021
Trends & Analysis
Part II: An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report
Barbara W. Unger
March 24, 2021
Trends & Analysis
Part I: An Analysis Of MHRA’s Latest Annual GMP Inspection Deficiencies Report
Barbara W. Unger
March 17, 2021
Trends & Analysis
FDA FY2020 Drug Inspection Observations and Trends
Barbara W. Unger
February 4, 2021